The U.S. Food and Drug Administration on Friday granted approval for Tandem Diabetes Care's software program that uses readings from a continuous glucose monitor to predict and deliver corrective doses of insulin to patients using the company's t:slim X2 insulin pump.
No comments:
Post a Comment